Martin Wax, MD, Ophthalmology, New York, NY, University of Texas Southwestern Medical Center

MartinBruceWaxMD

Ophthalmology New York, NY

Glaucoma Related

Chief Medical Officer and Exec VP of R&D, PanOptica Inc., Bernardsville, NJ 07924

Overview of Dr. Wax

Martin B. Wax M.D. is currently the Chief Medical Officer and Executive Vice-President of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He was Vice President of R&D and Head of Ophthalmology Discovery Research and Preclinical Sciences at Alcon Laboratories in Ft. Worth, Texas from 2003-2008. He is currently a Clinical Professor of Ophthalmology and Visual Sciences at the Rutgers Medical School in Newark, NJ. Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and was a postdoctoral fellow first in Neuropharmacology and then in Glaucoma at the University of Pennsylvania School of Medicine in Philadelphia. Prior to entering industry as the head of Ophthalmology Research at Pharmacia Corporation in 2002, he held the distinguished Research to Prevent Blindness Chair as a Professor of Ophthalmology at Washington University School of Medicine in St. Louis, MO.

He has coauthored more than 200 publications including peer-reviewed articles, abstracts and chapter in books and is an internationally recognized scientific expert in the field of glaucoma and ocular pharmacology. Dr. Wax was the recipient of the 1991 Robert E. McCormick Scholarship and the 1995 Lew R. Wasserman Merit Award for his contributions to basic eye research, the 1999 Rudin Prize from the NY Academy of Medicine, the 2001 Senior Investigator Award from Research to Prevent Blindness, the 2003 Clinician-Scientist Award from the American Glaucoma Society and the 2010 Barany Prize in Ocular Pharmacology from ISER. He is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology and the American Glaucoma Foundation. He currently serves on several national and international Scientific Advisory Committees, Editorial Boards, and corporate Boards.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFELLOWSHIP
  • Wills Eye Hospital
    Wills Eye HospitalRESIDENCY
  • University of Southern California - LAC+USC Medical Center
    University of Southern California - LAC+USC Medical CenterINTERNSHIP
  • Keck School of Medicine of USC
    Keck School of Medicine of USCMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2016 - 2021
  • NJ State Medical License
    NJ State Medical License 2013 - 2021
  • TX State Medical License
    TX State Medical License 2007 - 2019
  • IL State Medical License
    IL State Medical License 1996 - 2017
  • MO State Medical License
    MO State Medical License 1990 - 2017
  • PA State Medical License
    PA State Medical License 1979 - 2016
  • American Board of Ophthalmology Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of Neovascular (Wet) AMD
    PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of Neovascular (Wet) AMDOctober 11, 2019 21:26
  • PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 – a Novel, Topical Anti-VEGF Eye Drop
    PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 – a Novel, Topical Anti-VEGF Eye DropOctober 07, 2017 10:39
  • PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop
    PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye DropOctober 17, 2016 10:42

Grant Support

  • Heat Shock Proteins And Their Antibodies In GlaucomaNational Eye Institute1998–2002
  • Ocular Hypertension Treatment Study (OHTS)National Eye Institute1994–2002
  • Vacuolar H+/Atpase In The Ciliary EpitheliumNational Eye Institute1996–1998
  • G Protein Effector System In Ciliary Epithelial CellsNational Eye Institute1991–1994
  • G Protein Effector Systems In Ciliary Epithelial CellsNational Eye Institute1990
  • G Protein Effector Systems In Ciliary Epithelial CellsNational Eye Institute1989–1990
  • Adenylate Cyclase Desensitization In Iris/Ciliary BodyNational Eye Institute1988
  • Adenylate Cyclase Desensitizatin In Iris/Ciliary BodyNational Eye Institute1986–1987

Hospital Affiliations